Drug intelligence / Profile preview

CH505W53

Development stage: Phase 1
Lead developer: CHAVD
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

CH505W53 is an HIV envelope protein (Env) derived from the CH505 lineage of HIV-1 viruses. It represents the week 53 variant of the CH505 transmitted/founder (TF) virus. This protein is used as a component in HIV vaccine development, specifically in lineage-based vaccine designs targeting the CD4 binding site (CD4bs) of HIV. CH505W53 is typically administered as a gp120 protein adjuvanted with GLA-SE (a TLR4 agonist) in clinical trials.

Beyond the preview

Go deeper on CH505W53.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CH505W53.

Explore the full profile